AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01309243
Drug: EFV/FTC/TDF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
Trial: NCT02779283
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02779283
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00002802
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002802
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02779283
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02779283
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00545363
Drug: Ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive ibandronate 150 mg QM orally for 6 months.
Trial: NCT00062686
Drug: GW572016
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01141270
Drug: AFOLIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single sc injection, 225 IU
Trial: NCT01850823
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03009019
Drug: DFN-15 Active
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03248141
Drug: Hemophilia A standard half-life
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xyntha and other standard half-life agents
Trial: NCT03248141
Drug: Hemophilia A extended half-life
RxNorm normalized name: propranolol hydrochloride Extended Release Oral Capsule [Half-Betadur CR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eloctate and Adynovate
Trial: NCT02194842
Drug: Ra223
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02248636
Drug: Cholinesterase inhibitor
RxNorm normalized name: Acetylcholinesterase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
Trial: NCT03034057
Drug: Sayana Press
RxNorm normalized name: garden cress sprout extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sayana Press in the Uniject injection system
Trial: NCT02248636
Drug: Sham discontinuation
RxNorm normalized name: guaifenesin / hydrocodone bitartrate / phenylephrine hydrochloride Oral Solution [Entex HC Discontinued]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
Trial: NCT02562950
Drug: GLPG1837 500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
Trial: NCT02562950
Drug: GLPG1837 1000 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
Trial: NCT04839549
Drug: Dextenza 0.4Mg Ophthalmic Insert
RxNorm normalized name: Dextenza 0.4mg Ophthalmic Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextenza 0.4Mg Ophthalmic Insert
Trial: NCT04839549
Drug: Fluoromethalone .01%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoromethalone .01%
Trial: NCT01814826
Drug: MLN4924
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MLN4924 intravenously (IV) in AML participants in a 28-day cycle:~* MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles
Trial: NCT00533624
Drug: Mycophenolate Sodium Delayed Release Tablets
RxNorm normalized name: mycophenolic acid Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myfortic® 1,440 mg/day
Trial: NCT04848181
Drug: no treatment received
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: no treatment received before TURP
Trial: NCT03342118
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group was treated with normal saline before endoscopy
Trial: NCT00899379
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Rizatriptan, Oral Tablet
Trial: NCT04151706
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/dose Q24h IV. Infused over 2 hours. 1 dose per day x 2 consecutive days x 60 mg/kg/dose = 120 mg/kg
Trial: NCT00212277
Drug: Norethindrone,Ethinyl Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03176446
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with epinephrine 1: 100000 1.8 mL
Trial: NCT01503983
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
Trial: NCT01837290
Drug: saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion to facilitate blinding
Trial: NCT03375632
Drug: FYU-981
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dosing for 14 weeks
Trial: NCT03375814
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The group that takes Placebo Oral Tablet. They received the conventional treatment and Placebo Pills..
Trial: NCT00986115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
Trial: NCT04575675
Drug: Beta blocker
RxNorm normalized name: Beta blocker
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardio-selective beta-blocker, including carvedilol, bisoprolol, metoprolol or nebivolol
Trial: NCT05181943
Drug: Conventional symptomatic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment using oracure, BBC spray, miconaz three times daily
Trial: NCT00309920
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00309920
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00309920
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003185
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02467413
Drug: BAC
RxNorm normalized name: Bacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
Trial: NCT00637832
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00637832
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00637832
Drug: prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01767129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One capsule twice daily for 14 days
Trial: NCT01110720
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Nasal Spray BID IN 52 weeks
Trial: NCT02154477
Drug: placebo (intranasal saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline
Trial: NCT01172639
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate tablet
Trial: NCT01037413
Drug: EXC 001
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of EXC 001 and placebo
Trial: NCT01037413
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple intradermal injections of EXC 001 and placebo
Trial: NCT00809341
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Trial: NCT00809341
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m\^2 on Day 1 of each cycle as part of R-CHOP.
Trial: NCT00809341
Drug: High-dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/kg/day on Days 2-5 of HiCy.
Trial: NCT00237614
Drug: intravenous and oral N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01843452
Drug: CAPECITABINE
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 825mg/m2 orally twice daily on study days 1 through 45.
Trial: NCT01487902
Drug: ADT
RxNorm normalized name: Radtue
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
Trial: NCT01487902
Drug: No ADT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel-prednisolone (TAX327 regimen) alone
Trial: NCT02477449
Drug: 9% Saline (NS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infusion for 24 hours
Trial: NCT02125136
Drug: Gem/nab-Pac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle
Trial: NCT02125136
Drug: FOLFIFINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patient receive:~2 cycles gemcitabine/nab-paclitaxel (\[Gem/nab-Pac\]; duration of each cycle 28 days)~Then:~Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.~To be repeated on D1 of each cycle.
Trial: NCT00702416
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 µg iv prn (in the intraoperative period)
Trial: NCT01650519
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 mg intravenous ibuprofen administered intravenously over 10 minutes.
Trial: NCT00616746
Drug: Ethanol
RxNorm normalized name: Ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV
Trial: NCT01876771
Drug: [177]Lu-DOTA-TATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide receptor radionuclide therapy (PPRT)
Trial: NCT01412632
Drug: Remifentanil, propofol and citanest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iv remifentanil iv propofol im citanest
Trial: NCT04402203
Drug: Only Standard Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment included oxygen inhalation, oral or intravenous rehydration, electrolyte correction, antipyretics, analgesics, antibiotics and antiemetic drugs \& the medication any patient is on due to any concomitant diseases.
Trial: NCT00944892
Drug: REGN475
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 Administrations of REGN475 within 24 weeks.
Trial: NCT04023149
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: placebo; Pharmaceutical form: solution; Route of administration: oral gargle.
Trial: NCT02348372
Drug: GSK1278863A Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching size, shape and color
Trial: NCT02348372
Drug: GSK1278863A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A round, biconvex, white film coated tablet
Trial: NCT02901145
Drug: Nivolumab,low dose cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
Trial: NCT02633397
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
Trial: NCT02275299
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
Trial: NCT00547183
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
Trial: NCT00632008
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
Trial: NCT02480751
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04596826
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration
Trial: NCT03666884
Drug: COE 2*1 (Restasis) + PFAT Refresh Single dose) 8*1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clinical improvement in oxford scale, ocular surface disease index, schirmers test, tear break up time, fluorescein staining of eye
Trial: NCT02874651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
Trial: NCT01824433
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: fluoxetine 20-60mg qd
Trial: NCT04596033
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lymphodepletion drug
Trial: NCT00344422
Drug: Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00494208
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone ester
Trial: NCT02859441
Drug: E10030
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
Trial: NCT00371852
Drug: lactoserum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005969
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005969
Drug: Tretinoin Liposome
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposome by vein (IV) over 30 minutes every other day for 28 days
Trial: NCT00331955
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03972397
Drug: Patient-controlled analgesia (PCA)
RxNorm normalized name: lauryl PCA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will have access to the standard PCA (Patient-Controlled Analgesia) offered at the Memorial Hermann Hospital - Texas Medical Center. The PCA drug will be Dilaudid (hydromorphone). Initial dosing will be per the standard hospital protocol of 0.2 mg demand dose, 10-minute lockout, 2 mg per hour max, 0.4 mg rescue dose. Adjustments to the PCA dosing will be made based on clinical needs.
Trial: NCT01315444
Drug: Stop PPI gradually
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01538225
Drug: Sativex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.~Duration: 2 weeks
Trial: NCT01538225
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo~Same frequency and dosage form as Sativex.~Duration: 2 weeks
Trial: NCT02562859
Drug: 500 mg GLPG1837 as oral suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 500 mg GLPG1837 administered as oral suspension
Trial: NCT02562859
Drug: 500 mg GLPG1837 as oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single dose of 500 mg GLPG1837 administered as oral tablet
Trial: NCT00092326
Drug: MK0966, rofecoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01669083
Drug: GSK557296 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
Trial: NCT00799747
Drug: AZD4017
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ascending single doses (start dose 2 mg), oral suspension
Trial: NCT01669083
Drug: GSK557296 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
Trial: NCT01669083
Drug: GSK557296 dose 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
Trial: NCT01669083
Drug: GSK557296 dose 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
Trial: NCT00799747
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT00309270
Drug: Campath-1H
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01618695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Core study: Week 0 to Week 18 Once daily placebo.~Extension study:~Week 19 to Week 22 Once daily placebo, Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day.
Trial: NCT02705625
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo manufactured to mimic MIV-711 capsule.
Trial: NCT03347266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: water for injection
Trial: NCT02943707
Drug: drugs such as Ursodeoxycholic Acid tablets
RxNorm normalized name: ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
Trial: NCT04150341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will be administered by inhalation in the morning for 14 days during each period. A washout period of at least 21 days will exist between subsequent periods.
Trial: NCT04346446
Drug: Convalescent Plasma Transfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Convalescent Plasma Transfusion
Trial: NCT01649297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo matching empagliflozin (low dose qd)
Trial: NCT01649297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo matching empagliflozin (low dose bid)
Trial: NCT01649297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo matching Empagliflozin (high dose qd)
Trial: NCT01649297
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients receive placebo matching Empagliflozin (high dose bid)